

Press release from Emotra AB (publ)

Göteborg, October 12, 2015

Emotra announces the results of its new share issue with right of priority

The closing date for registering interest in Emotra AB's ("Emotra") rights issue was October 7, 2015. The limit for this rights issue, in which the general public was also invited to participate, was approximately 12.3 MSEK. Approximately 81.7% of the shares were subscribed, including subscription commitments. Based on the above numbers, guaranteed subscribers will be allotted shares amounting to appr. 2.25 MSEK. This new share issue will provide Emotra with approximately 11.3 MSEK after issue expenses, as well as about 60 new shareholders. We plan on sending out account statements today. Since this new share issue was not over-subscribed, the Company will not need to exercise its over-allocation option in order to widen the shareholder base.

Comments from Claes Holmberg, Emotra's CEO

"We are in an early commercialisation phase. Gaining market acceptance is imperative for achieving a healthy sales volume. As I have previously stated, it is very important that we establish consensus about the method's safety, effectiveness, reliability and reproducibility. This consensus will facilitate a market launch of the product in Europe. The capital Emotra has raised through this share issue will provide us with the means for, primarily, completing our ongoing multi-centre study. I would like to thank everyone who has subscribed for shares in this new issue."

Subscription and allotment

The subscription rate for this new share issue was approximately 81.7%, including subscription commitments. Based on the above numbers, guaranteed subscribers will be allotted shares amounting to appr. 2.25 MSEK. The result is the issue of 4,326,300 new shares. The new issue will provide the company with 11.3 MSEK after issue expenses. 2,859,848 shares (approximately 66% of the new issue volume) will be allocated through right of priority. Shareholders who are allotted new shares without right of priority will be receiving account statements. We expect to send these account statements today, October 12, 2015.

Number of Shares and share capital

Once this rights issue has been registered with Bolagsverket (The Swedish Companies Registration Office), Emotra's share capital will amount to 1,760,804.10 SEK, divided among 9,517,860 shares.

Trading in PSS

Trading in PSS (Paid Subscribed Shares) will be carried out on AktieTorget until the share issue has been registered at Bolagsverket. We expect this registration to be completed at the end of October 2015.

Financial Advisor

Emotra's Financial Advisor in connection with this new share issue is Sedermera Fondkommission.

For questions about the new share issue, please contact:

Sedermera Fondkommission
Telephone: +46 431 47 17 00
E-mail: info@sedermera.se

For further information about the Company, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.